These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 17602923
1. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease. Perazella MA, Rodby RA. Am J Med; 2007 Jul; 120(7):561-2. PubMed ID: 17602923 [No Abstract] [Full Text] [Related]
2. Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. Cowper SE, Kuo PH, Bucala R. Arthritis Rheum; 2007 Oct; 56(10):3173-5. PubMed ID: 17907160 [No Abstract] [Full Text] [Related]
3. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Br J Dermatol; 2008 Mar; 158(3):607-10. PubMed ID: 18076707 [Abstract] [Full Text] [Related]
4. Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Jamboti J. Intern Med J; 2007 Jul; 37(7):508-9; author reply 509. PubMed ID: 17547734 [No Abstract] [Full Text] [Related]
5. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease. Shenoy C. Am J Med; 2008 Jan; 121(1):e11; author reply e13. PubMed ID: 18187056 [No Abstract] [Full Text] [Related]
6. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. Goveia M, Chan BP, Patel PR. J Am Acad Dermatol; 2007 Oct; 57(4):725-7. PubMed ID: 17689832 [No Abstract] [Full Text] [Related]
7. Nephrogenic systemic fibrosis: is any contrast safe in renal failure? Endre ZH. Intern Med J; 2007 Jul; 37(7):429-31. PubMed ID: 17547720 [No Abstract] [Full Text] [Related]
10. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. Pedersen M. J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808 [No Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis: a dermatologist's perspective. Girardi M. J Am Coll Radiol; 2008 Jan; 5(1):40-4. PubMed ID: 18180008 [Abstract] [Full Text] [Related]
12. Clinical and histological findings in nephrogenic systemic fibrosis. Cowper SE, Rabach M, Girardi M. Eur J Radiol; 2008 May; 66(2):191-9. PubMed ID: 18325705 [Abstract] [Full Text] [Related]
13. The impact of NSF on the care of patients with kidney disease. Abu-Alfa A. J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009 [Abstract] [Full Text] [Related]
14. [Nephrogenic systemic fibrosis]. Breitschaft A, Stahlmann R. Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227 [Abstract] [Full Text] [Related]
15. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246 [Abstract] [Full Text] [Related]
16. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent]. van der Meij N, Keur I, van Lienden KP, Scheepstra CG, Bos JD. Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2898-903. PubMed ID: 18257437 [Abstract] [Full Text] [Related]
18. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium. Caccetta T, Chan JJ. Australas J Dermatol; 2008 Feb 29; 49(1):48-51. PubMed ID: 18186850 [Abstract] [Full Text] [Related]
19. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Abraham JL, Thakral C. Eur J Radiol; 2008 May 29; 66(2):200-7. PubMed ID: 18374532 [Abstract] [Full Text] [Related]